The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G.

Open source

DOI
10.1183/09031936.01.00092101
Published
2001-08-01
Container
Eur Respir J
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1183/09031936.01.00092101,
  title = {The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.},
  author = {Solèr M and  Matz J and  Townley R and  Buhl R and  O'Brien J and  Fox H and  Thirlwell J and  Gupta N and  Della Cioppa G.},
  year = {2001},
  journal = {Eur Respir J},
  doi = {10.1183/09031936.01.00092101},
  url = {https://doi.org/10.1183/09031936.01.00092101}
}

RIS

TY  - JOUR
TI  - The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
AU  - Solèr M
AU  -  Matz J
AU  -  Townley R
AU  -  Buhl R
AU  -  O'Brien J
AU  -  Fox H
AU  -  Thirlwell J
AU  -  Gupta N
AU  -  Della Cioppa G.
PY  - 2001
JO  - Eur Respir J
DO  - 10.1183/09031936.01.00092101
UR  - https://doi.org/10.1183/09031936.01.00092101
ER  - 

APA

M, S., J, M., R, T., R, B., J, O., H, F., J, T., N, G., & G., D. C. (2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.. Eur Respir J. https://doi.org/10.1183/09031936.01.00092101

Source records